Roche Appeals FDA Move Against Avastin

June 27, 2011
The FDA decided in December that Avastin was not an effective treatment for breast cancer and said it would take steps to revoke market approval and change the drug's label.

Swiss pharmaceutical giant Roche on June 28 began a two-day appeal asking the U.S. Food and Drug Administration to allow the top-selling drug Avastin to be used for breast cancer. The FDA decided in December that Avastin was not an effective treatment for breast cancer and said it would take steps to revoke market approval and change the drug's label.

The U.S. regulatory move followed the recommendation of an expert panel that said the drug, also known as bevacizumab, carries risks such as severe high blood pressure and hemorrhage and does not prolong overall survival in women suffering from breast cancer.

Avastin had been approved for treatment of advanced breast cancer under the FDA's accelerated approval program, which allows provisional approval of medicines for cancer or other life-threatening diseases.

The panel's recommendation did not affect the use of Avastin to treat other cancers, including colon and lung cancers.

Genentech, the Roche-owned U.S .pharmaceutical company that makes Avastin, released a statement last month detailing its arguments on why Avastin should stay on the market, which would be presented at the FDA hearing.

"When used with traditional chemotherapies, Avastin delays cancer progression and improves response," said the statement, which also offered lengthy arguments about how the clinical data should be interpreted.

Avastin remains FDA-approved for use in combination with the chemotherapy drug paclitaxel for first-line treatment of metastatic HER2-negative breast cancer until the hearing ends and FDA makes a final decision, the company said.

European medical experts have urged that the drug be restricted to use in combination with paclitaxel only instead of other forms of chemotherapy because benefits were uncertain.

Copyright Agence France-Presse, 2011

Popular Sponsored Recommendations

Empowering the Modern Workforce: The Power of Connected Worker Technologies

March 1, 2024
Explore real-world strategies to boost worker safety, collaboration, training, and productivity in manufacturing. Emphasizing Industry 4.0, we'll discuss digitalization and automation...

3 Best Practices to Create a Product-Centric Competitive Advantage with PRO.FILE PLM

Jan. 25, 2024
Gain insight on best practices and strategies you need to accelerate engineering change management and reduce time to market. Register now for your opportunity to accelerate your...

Transformative Capabilities for XaaS Models in Manufacturing

Feb. 14, 2024
The manufacturing sector is undergoing a pivotal shift toward "servitization," or enhancing product offerings with services and embracing a subscription model. This transition...

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!